Is Buying Cytomx Therapeutics Inc (NASDAQ:CTMX), Having Lower Short Interest a Winning Strategy?

June 29, 2018 - By Jane Hopkins

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Logo

The stock of Cytomx Therapeutics Inc (NASDAQ:CTMX) registered a decrease of 0.9% in short interest. CTMX’s total short interest was 1.03 million shares in June as published by FINRA. Its down 0.9% from 1.04M shares, reported previously. With 292,500 shares average volume, it will take short sellers 4 days to cover their CTMX’s short positions. The short interest to Cytomx Therapeutics Inc’s float is 3.76%.

The stock decreased 0.26% or $0.06 during the last trading session, reaching $22.8. About 111,945 shares traded. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has risen 80.84% since June 29, 2017 and is uptrending. It has outperformed by 68.27% the S&P500.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States. The company has market cap of $888.23 million. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. It currently has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.

More notable recent CytomX Therapeutics, Inc. (NASDAQ:CTMX) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For June 1, 2018” on June 01, 2018, also Benzinga.com with their article: “44 Biggest Movers From Yesterday” published on June 05, 2018, Nasdaq.com published: “CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel” on June 14, 2018. More interesting news about CytomX Therapeutics, Inc. (NASDAQ:CTMX) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on June 01, 2018 as well as Globenewswire.com‘s news article titled: “CytomX to Present at the Jefferies 2018 Healthcare Conference” with publication date: May 31, 2018.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: